Mark C. Markowski, MD, PhD, discusses the evaluation of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.
Mark Christopher Markowski, MD, PhD
Advertisement
Articles by Mark Christopher Markowski, MD, PhD
Mark C. Markowski, MD, PhD, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.
Mark Christopher Markowski, MD, PhD, discusses the safety and efficacy of VERU-111 in patients with metastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
2
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
3
Immune-Targeting Vaccine Shows Promise Intercepting Cancer in Patients With Lynch Syndrome
4
ILUSTRO Trial Signals Role for First-Line Zolbetuximab-Based Triplet for Biomarker-Selected Gastric Cancer
5